You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ECCCHO: Effective Combat Casualty Care Handoff Operations
SBC: TIER 1 PERFORMANCE SOLUTIONS LLC Topic: DHA17B002Approximately 70% of sentinel events in medical care are related to communication mishaps, and despite regular and frequent occurrence, an even higher percentage (80%) of severe medical errors are related to miscommunication during handoffs (i.e., the transferring of information, responsibility, and authority for patient care from one provider to another). The TiER1 team proposes to address challe ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Handoff Training for Combat Casualty Care (HTC3) Framework
SBC: Perceptronics Solutions, Inc. Topic: DHA17B001This proposal is to develop a Handoff Training for Combat Casualty Care (HTC3) Framework.Training is the crux of the handoff problem today. Patient handoffs are a crucial part of casualty care, both in military and civilian environments; and today handoffs are being performed in less than optimal fashion, with ineffective communications accounting for 80% of the handoff errors. Our new HTC3 Framew ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Oxygen Production and Delivery on Demand
SBC: GLOBAL RESEARCH & DEVELOPMENT INC Topic: DHA17B005This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Probabilistic Pharmacokinetic Models for Diagnosis, Prognosis, and Personalized Treatment
SBC: BARRON ASSOCIATES, INC. Topic: DHA17B003Clinicians have recognized that the nature of diseases can be highly individual resulting in different patterns of onset and progression. In turn, the response of an individual to drugs is also unique and governed by a variety of factors. Pharmacokinetic models represent the movement of a drug through the body, and personalized pharmacokinetic models aim to capture the unique responses of specific ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Functionalized, Therapeutic-Loaded Liposomes for the Acute Treatment of TBI
SBC: LUNA INNOVATIONS INCORPORATED Topic: DHA18A001Traumatic brain injury is a common problem in both the military and civilian communities, but current treatment protocols are focused on managing symptoms and fail to prevent significant long-term repercussions. In the proposed program, Luna will demonstrate the feasibility of a liposome-based therapeutic delivery system capable of delivering hydrophilic and hydrophobic therapeutics to the traumat ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Brain Targeting Nanoparticle for Drug Delivery in Traumatic Brain Injury
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: DHA18A001There is an urgent need to bypass or cross the blood brain barrier (BBB) to deliver drugs for TBI treatment. This project aims to develop targted intranasally delivered, magnetically propulsed, and targted nanoparticles for traumatic brain injury (TBI). In Phase I, we will demonstrate the design, fabrication, and in vitro characterization of proposed drug laden magnetic nanoparticles as well as co ...
STTR Phase I 2018 Department of DefenseDefense Health Agency -
Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases
SBC: CFD RESEARCH CORPORATION Topic: CBD18A001In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Virus-Like Particle Based pan-Marburgvirus Vaccine
SBC: LUNA INNOVATIONS INCORPORATED Topic: CBD18A002Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: Flow Pharma, Inc. Topic: CBD18A002Flow Pharma, Inc. is a biotechnology company in the San Francisco Bay Area developing fully synthetic cytotoxic T lymphocyte (CTL)stimulating peptide vaccines for Marburg virus. The FlowVax vaccine platform allows us to create dry powder formulations of biodegradablemicrospheres and TLR adjuvants incorporating class I and class II T cell epitopes. FlowVax vaccines can be designed for delivery by i ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense -
Marburg Virus Prophylactic Medical Countermeasure
SBC: MAPP BIOPHARMACEUTICAL, INC. Topic: CBD18A002There are currently no vaccines or therapeutics available for Marburg Virus Disease (MVD). Given the specter of weaponization and the terriblemorbidity and high mortality rate of MVD, this represents a critical threat to the operational readiness of the Warfighter. While traditionalvaccines have proven to be a huge contribution to public health, they do have some limitations especially in the cont ...
STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense